Proliferative and cytokine responses to class II HER-2/neuassociated peptides in breast cancer patients

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 2015-2024

  Tuttle, Todd M ^a   Anderson, Brett W ^a   Thompson, William E ^a   Lee, Jeffrey E ^a   Sahin, Aysegul ^a   Smith, Terry L ^a   Grabstein, Kenneth H ^b   Wharton, J Taylor ^a   Ioannides, Constantin G ^a,c   Murray, James L ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA DR4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; ONCOPROTEIN;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HLA SYSTEM; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL DIVISION; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; SEQUENCE HOMOLOGY, AMINO ACID; STIMULATION, CHEMICAL; T-LYMPHOCYTES;

EID: 0031854348     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cheever, M. A, Britzmann-Thompson, D., Klarnet, J. P., and Greenberg, P. D. Antigen-driven long-term cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy persist long-term as functional memory T cells. J. Exp. Med., 163: 1100-1112, 1986.
2. Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J, Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst., 86: 1159-1166, 1994.
3. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
4. Mitchell, M. S. Attempts to optimize active specific immunotherapy for melanoma. Int. Rev. Immunol., 7: 331-347, 1991.
5. Topalian, S L. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol., 6: 741-745, 1994.
6. Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., and Rosenberg, S. A. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465, 1994.
7. Topalian, S. L., Gonzales, M. J., Parkhurst, M., Li, Y. F., Southwood, S., Sette, A., Rosenberg, S. A., and Robbins, P. F. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted Tyrosinase epitopes. J. Exp. Med., 183: 1965-1971, 1996.
8. Yoshino, I., Goedegebuure, P. S., Peoples, G. E., Lee, K-Y., and Eberlein, T. J Human tumor infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70. J. Immunol., 153: 4149-4158, 1994.
9. Takahashi, T., Chapman, P. B., Yang, S. Y., Hara, I., Vijayasandhi, S., and Houghton, A. N. Reactivity of autologous CD4+ T lymphocytes against human melanoma. J. Immunol., 154: 772-779, 1995.
10. Dadmarz, R., Sgagias, M K., Rosenberg, S A., and Schwartzentruber, D. J. CD4+ T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC-class II restricted fashion. Cancer Immunol. Immunother., 40: 1-9, 1995.
11. Heike, M., Schlaak, J., Schulze-Bergkamen, H., Heyl, S. Herr, W., Schmitt, U., Schneider, P. M., and Meyer zum Buschenfelde, K. H. Specificities and functions of CD4+ HLA- class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens. J. Immunol., 156: 2205-2213, 1996.
12. Qin, H., Chen, W., Takahashi, M., Disis, M. L., Byrd, D. R., McCahill, L., Bertram, K. A., Fenton, R. G., Peace, D. J., and Cheever, M. A. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res., 55: 2984-2987, 1995.
13. Gjersen, M. K., Bakka, A., Breivik, J., Saeterdal, I., Solheim, B. G., Soreide, O., Thornsby, E., and Gaudernack, G. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation. Lancet, 346: 1399, 1995.
14. Takahashi, M., Chen, W., Byrd, D., Disis, M. L., Huseby, E., McCahill, L., Nelson, H., Peace, D., Qin, H. L., Shimada, H., Okuno, K., Yasutomi, M., and Cheever, M. A. Antibody responses to ras proteins in patients with colon cancer. Clin. Cancer Res., 1: 1071-1077, 1995.
15. Tilkin, A. F., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M. C., Lefrere, I., Carlu, C., Roy, M., Kayibanda, M., Bellet, D., Guillet, J. G., and Bressac-dePaillerets, B. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol., 25: 1765-1769, 1995.
16. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R. B., Moe, R., and Cheever, M. A. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.
17. Fisk, B., Hudson, J. M., Kavanagh, J., Wharton, J. T., Murray, J. L., Ioannides, C. G., and Kudelka, A. P. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res., 17: 45-54, 1997.
18. Lee, J. E., Lowy, A. M., Thompson, W. A., Lu, M., Bell, B., Skibber, J. M., Evans, D. B., Curley, S. A., Mansfield, P. F., and Reveille, J. D. Association of gastric adenocarcinoma with the human leukocyte antigen class II gene. DQB1*0301. Gastroenterology, 111: 426-432, 1996.
19. Lee, J. E., Reveille, J. D., Ross, M. I., and Platsoucas, C. D. HLA-DQB1*0301 association with increased melanoma risk. Int. J. Cancer, 59: 510-513, 1994.
20. Lee, J. E., Lu, M., Mansfield, P. F., Platsoucas, C. D., Reveille, J. D., and Ross, M. I. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer (Phila.), 78: 758-763, 1996.
21. Lee, J. E., Loflin, P. T., Laud, P. R., Lu, M., Reveille, J. D., and Lawlor, D. A. The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p. Tissue Antigens, 47: 117-121, 1996.
22. Marsh, S. G. E., and Bodmer, J. G. HLA class II region nucleotide sequences. Tissue Antigens, 45: 258-280, 1995.
23. Kropshofer, H., Max, H., Muller, C. A., Hesse, F., Stevanovic, S., Jung, G., and Kalbacher, H. Self-peptide released from class II HLA-DR1 exhibits a hydrophobic two-residue contact motif. J. Exp. Med., 175: 1799-1803, 1992.
24. Malcherek, G., Falk, K., Rotzschke, O., Rammensee, H-G., Stevanovic, S., Gnau, V., Jung, G., and Melms, A. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int. Immunol., 5: 1229-1237, 1993.
25. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H-G. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics, 39: 230-242, 1994.
26. Wucherpfennig, K. W., and Strominger, J. L. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J. Exp. Med., 181: 1597-1601, 1995.
27. Hammer, J., Valsasnini, P., Tolba, K., Bolin, D., Higelin, J., Takacs, B., and Sinigaglia, F. Promiscuous and allele-specific anchors in HLA-DR binding peptides. Cell, 74: 197-203, 1993.
28. Sinigaglia, F., and Hammer, J. Motifs and supermotifs for MHC class II binding peptides. J. Exp. Med., 181: 449-451, 1995.
29. Marshall, K. W., Wilson, K. J., Liang, J. Woods, A., Zaller, D., and Rothbard, J. B. Prediction of peptide affinity to HLA-DRB1*0401. J. Immunol., 154: 5927-5933, 1995.
30. Ioannides, C. G., Fisk, B., Fan, D., Biddison, W. A., Wharton, J. T., and O'Brian, C. A. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptides derived from the HER-2/neu proto-oncogene. Cell. Immunol., 151: 225-234, 1993.
31. Ioannides, C. G., and Freedman, R. S. T cell responses to ovarian tumor vaccines. Int. Rev. Immunol., 7: 349-364, 1991.
32. Fleiss, J. L. Statistical Methods for Rates and Proportions, pp. 83-85. John Wiley & Sons, New York, 1973.
33. Sheen-Chen, S-M., Chou, F-F., Eng, H-L., and Chen, W-J. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery (St. Louis), 116: 510-515, 1994.
34. Casoli, C., Zanelli, P., Adorni, A., Starcich, B. R., and Neri, T. Serological and molecular study on the HLA phenotype of female breast cancer patients (Letter). Eur. J. Cancer, 30: 1207-1208, 1994.
35. Kamogawa, Y., Minasi, L. A., Carding, S. R., Bottomly, K., and Flavell, R. A. The relationship of IL-4- and IFN-γ-producing T cells studies by lineage ablation of IL-4 producing cells. Cell, 75: 985-995, 1993.
36. Hammer, J., Gallazzi, F., Bono, E., Karr, R. W., Guenot, J., Valsasnini, P., Nagy, Z. A., and Sinigaglia, F. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med., 181: 1847-1855, 1995.
37. Barker, R. N., and Elson, C. J. Multiple self epitopes on the Rhesus polypeptides stimulate immunologically ignorant human T cells. Eur. J. Immunol., 24: 1578-1582, 1994.
38. Elson, C. J., Barker, R. N., Thompson, S. J., and Williams, N. A. Immunologically ignorant autoreactive T cells, epitope spreading and repertoire limitation. Immunol. Today, 16: 71-76, 1995.
39. Nanda, N. K., and Sercarz, E. E. Induction of anti-self-immunity to cure cancer. Cell, 82: 13-17, 1995.
40. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu-protooncogene recognized by ovarian tumor specific CTL lines. J. Exp. Med., 181: 2709-2717, 1995.
41. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
42. Allison, J. P., Hurwitz, A. A., and Leach, D. R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol., 7: 682-686, 1995.